Start with what life feels like now
Where does TPE fit when symptoms follow an exposure?
We help people with symptoms following an exposure or illness by reviewing their history and current findings so that they can make informed choices about getting back to everyday life.
How we look at the whole picture
You noticed a change after an illness or exposure, but you still have questions about what is happening now.
Fatigue, sensitivities or trouble thinking may be disrupting work, home life and plans.
You do not need to know which treatment to ask for. Start with what has changed and what you want to be able to do again.
The 7 Domains of Recovery™
Your symptoms may belong in the same conversation.
An exposure history is one part of the picture. We also consider immune function, energy, cognition and the other domains, including alternative explanations for symptoms.
Neuregen's proprietary 7 Domains of Recovery framework organizes that conversation around seven connected parts of your life and health. We consider all seven, then focus the evaluation on the questions your history raises.
Explore our clinical framework- 1Brain function & neural networks
What has changed in your memory, concentration, balance or sensory tolerance?
- 2Autonomic & nervous system regulation
What happens when you stand, move, rest or encounter stress?
- 3Immune function & neuroinflammation
What immune history, reactions or symptoms need a closer look?
- 4Brain energy & metabolic health
What affects your energy through the day and after activity?
- 5Structure, stability & body-to-brain signals
How do pain, posture, movement and stability affect what you can do?
- 6Psychological flexibility & behavioral recovery
How are mood, stress and patterns of coping affecting your day?
- 7Life, relationships & environment
What demands, relationships and support shape your recovery?
A plan starts with the things you want to do again.
We review the timeline, previous testing and care, and any ongoing exposure concerns. The next assessments depend on what remains uncertain.
01
Tell us what you want your life to look like
We start with what has changed, what you have tried, and the activities you most want to return to.
02
Answer the questions the history leaves open
We review prior reports and select relevant assessments. You should understand what each assessment is meant to clarify.
03
Agree on the priorities and the first steps
We discuss the findings, possible approaches, costs and practical constraints. The plan sets an order that fits your situation.
04
Check what changes and adjust together
We compare your response with the starting point, including daily function. If something is not helping, we discuss what needs to change.
Only then do we discuss which therapies, if any, belong in your plan. The choice depends on the findings, the evidence, your preferences and how you respond.
Talk through your situationBlood Rehabilitation · Therapeutic Plasma Exchange
TPE for Mold-Related & Lyme-Associated Neurologic Illness
Your plasma carries more than nutrients — it can carry the inflammation, antibodies, and toxins that are quietly working against your brain. TPE clears it and replaces it with a cleaner foundation to rebuild on.
Clinically: An apheresis-based exchange that reduces circulating inflammatory mediators, pathogenic antibodies, and immune complexes — offered as an investigational tool in selected patients with neurologic illness attributed to mold or environmental exposure, with explicit informed consent and no outcome guarantee.
Conceptual artwork for the care discussion. Individual findings and treatment options require clinical evaluation.
Why the immune system becomes the target
In selected patients with complex neurologic illness attributed to mold or environmental exposure, circulating immune mediators — antibodies, inflammatory cytokines, immune complexes — may be contributing to ongoing nervous-system dysfunction. TPE is designed to reduce these circulating factors by removing and replacing plasma.
Exposure assessment and remediation are part of Neuregen's plan for these patients, not optional add-ons. Removing plasma constituents without addressing ongoing exposure is incomplete clinical reasoning. The 7-Domain framework maps this explicitly to Domain 3 (Immune & Neuroinflammatory Regulation) and Domain 7 (Life, Relationships & Environment).
Neuregen labels this use investigational because the direct evidence base for TPE in mold-related or CIRS-linked neurologic illness remains early-stage. That is said plainly at every consultation. Promising does not mean proven. Promising deserves serious investigation.
Domains most involved:
Every plan starts from the same map: the 7 Domains of Recovery.
How it fits your plan
TPE for mold-related neurologic illness sits in the Treat phase of the plan — after the exposure history, baseline immune workup, and environmental assessment have established that a circulating immune burden is a meaningful target. It is not a first-line intervention and is not offered before that groundwork is complete.
Blood therapies only make sense in relation to a specific clinical question. We review the indication, evidence and risks for TPE or EBOO separately, then consider whether either has a role alongside rehabilitation and your existing medical care.
We review your history, explain the findings, agree on next steps and check how you respond.
Potential Therapies
We use established medicine where it works, and emerging medicine where it makes sense.
These are options to discuss after evaluation, not a predetermined treatment plan. Each label refers to the condition or indication described beside that therapy; evidence can differ for another use. An evidence label does not mean FDA approval.
- Therapeutic Plasma Exchange (TPE)Evidence: Investigational
Investigational for mold-related and Lyme-associated neurologic illness. Offered with explicit informed consent and no outcome guarantee.
Where the evidence stands
Early-stage evidence for TPE in mold-related and CIRS-linked neurologic illness. Mechanistic rationale is grounded in the established role of TPE in removing circulating immune mediators — but direct, controlled evidence for this specific indication remains limited. Neuregen offers this approach within a comprehensive rehabilitation plan, after full medical review and informed-consent discussion.
Sources and what they support
- ASFA 2023 guidelines for therapeutic apheresis
Apheresis recommendations are indication-specific. An established use for one disease does not establish TPE for Alzheimer’s, Long COVID, MCAS or environmental illness.
How we grade evidence
Pricing
| Service | Price |
|---|---|
| Therapeutic plasma exchange, single procedure | Confirmed in writing at your Strategy Consultation |
| TPE seriesSeries length depends on the indication and your response | Confirmed in writing at your Strategy Consultation |
Neuregen is an out-of-network specialty clinic. Most therapies listed here are not covered by insurance; we provide itemized documentation you can submit to your insurer, and we tell you before any therapy which parts, if any, are typically reimbursed.
Financing options are reviewed at your Strategy Consultation before any plan is finalized.
The training behind this care
Neuregen brings the blood-therapy discussion into the same plan as neurologic, autonomic and functional care. We ask what a proposed intervention would change in daily life and how that change would be assessed.
Dr. David George: Board certifications and training in functional neurology, integrative psychiatry, and mental health; certified brain injury specialist.
Training most relevant to this area
- Member, American Society for Apheresis (ASFA)
- GCP Certified (NIDA)
These are the founder’s qualifications. We confirm the treating clinician and their role when discussing your plan.
See Dr. George’s full credentialsFrequently asked questions
Is TPE an established treatment for mold-related neurologic illness?
No. This application is classified investigational at Neuregen — early-stage evidence, offered with explicit informed consent and no outcome guarantee. TPE is established for classic autoimmune neurologic disease; its use in mold-related or CIRS-linked presentations draws on that mechanistic rationale but lacks the same direct evidence base.
Does addressing exposure matter if I am getting TPE?
Yes. Removing circulating immune mediators through TPE without addressing ongoing exposure to the triggering environment is incomplete clinical reasoning. Neuregen's plan for these patients includes exposure assessment and environmental context (Domain 7) alongside the blood-based intervention.
How does Neuregen decide if TPE belongs in my plan?
We determine this after a full medical review. The decision is based on the specific presentation, lab findings, immune workup, and exposure history — not on a standing protocol for this indication. No treatment plan is set before that review.
How is this different from IV infusions or ozone therapy for mold illness?
TPE is an apheresis-based procedure: plasma is physically separated and removed from blood cells, then replaced with a clean substitute. This is mechanistically distinct from IV infusions or simpler ozone protocols. The evidence base and the informed-consent conversation differ accordingly.
Start with a Strategy Consultation
Ongoing fatigue or difficulty thinking may already be limiting your work and family life. An evaluation can help organize what is known, what remains uncertain and whether further investigation is useful before considering blood therapy.
8090 N. 85th Way, Suite 100, Scottsdale, AZ 85258 · Mon–Thu, 9:00 AM – 5:30 PM